BGV V is a EUR 150 million fund and was launched in March 2023. We are actively looking for new seed and early stage investment opportunities in biotech companies for the BGV V Fund. Industry Biotech

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process.

2023年7月13日 · BGV V will build on the successful investment strategy of previous BGV funds: dedication to early-stage ventures and company creation and seeking out therapeutic innovations that stem from truly differentiated science and are supported by convincing experimental data.

BGV V Apply filters Currently in our portfolio. Artica Therapeutics. Artica uses the power of covalent chemistry to develop novel therapies for autoimmune and inflammatory disorders. Avidicure. Avidicure is developing novel approaches for immune cell activation and stimulation. ...

BioGeneration Ventures (BGV) is the early-stage strategy of the Forbion-BGV platform of funds, which also includes Forbion Ventures and Forbion Growth. BGV is located with Forbion in Naarden (NL) since inception.

BGV IV is a EUR 140 million fund and was launched in April 2020. The portfolio was completed in March 2023 with twelve portfolio investments.

Shaping new life-science ventures. Newsletter. Subscribe to our news releases. Subscribe

2023年11月2日 · The round was co-led by Thuja Capital and Seroba, with participation from InnovationQuarter and founding investor BGV. Proceeds from the financing will be used to advance Artica’s small molecule pipeline of novel covalent therapies.

2023年7月13日 · Endpoints News interviewed Managing Partner Edward van Wezel about the company's final close for BGV Fund V. Read the interview here.

2024年3月21日 · LEIDEN, The Netherlands – March 21, 2024 – Artica Therapeutics B.V. (Artica), a biotechnology company developing a pipeline of covalent small molecules for autoimmune and inflammatory disorders, today announced that industry veteran Piet Wigerinck PhD is joining the board as an independent non-executive director. Dr Wigerinck is a seasoned ...